Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination medication containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of abdominal pain and cramps associated with various gastrointestinal conditions, including irritable bowel syndrome (IBS) and other functional bowel disorders.
* Management of dysmenorrhea.
## Adult Dosing
* **Usual dose:** 1 tablet (mefenamic acid 250 mg / hyoscine butylbromide 10 mg) three times daily.
* **Maximum dose:** Not explicitly defined for the combination product, but individual component maximums should be considered. For mefenamic acid, the maximum daily dose is typically 1000 mg every 6 hours or 1500 mg per day in divided doses. For hyoscine butylbromide, doses exceeding 100 mg per day are generally not recommended.
## Pediatric Dosing
Dosing for children is not well-established for this specific combination product. Mefenamic acid can be dosed in children aged 6 months and older (e.g., 5-7 mg/kg/dose every 6-8 hours, maximum 4 doses per day, not to exceed 200 mg per dose or 800 mg per day). Hyoscine butylbromide pediatric dosing is also variable and typically lower than adult doses. Consultation with a pediatrician is recommended.
## Dose Adjustments
* **Renal Impairment:** Use with caution in patients with moderate to severe renal impairment. Mefenamic acid can cause renal toxicity.
* **Hepatic Impairment:** Use with caution in patients with hepatic impairment.
* **Elderly:** Use with caution, particularly if frail or with comorbidities.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or any component of the formulation.
* Active or history of gastrointestinal ulceration or bleeding.
* Severe renal or hepatic impairment.
* Myasthenia gravis.
* Tachycardia.
* Glaucoma (narrow-angle).
* Prostatic hypertrophy with urinary retention.
* Ileus or intestinal obstruction.
* Megaloblastic anemia.
* Third trimester of pregnancy.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, constipation, abdominal pain, dizziness, headache, rash.
* **Serious:** Gastrointestinal bleeding, perforation, renal failure, hepatic dysfunction, Stevens-Johnson syndrome, anaphylaxis, blurred vision, urinary retention, tachycardia.
## Key Drug Interactions
* **NSAIDs:** Increased risk of gastrointestinal bleeding and renal toxicity when used concurrently with other NSAIDs, aspirin, or corticosteroids.
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **ACE inhibitors, ARBs, diuretics:** Reduced antihypertensive effect and increased risk of renal impairment.
* **Lithium:** Mefenamic acid can increase serum lithium levels.
* **Methotrexate:** Increased methotrexate toxicity.
* **Potassium-sparing diuretics:** Increased risk of hyperkalemia.
* **Other anticholinergics:** Additive anticholinergic effects (e.g., increased dry mouth, constipation, blurred vision).
* **Dopamine antagonists:** May reduce the efficacy of prokinetic effects.
## Monitoring
* Monitor for signs and symptoms of gastrointestinal bleeding (e.g., melena, hematemesis).
* Monitor renal function, especially in patients with pre-existing renal disease or those receiving concomitant nephrotoxic drugs.
* Monitor liver function tests if prolonged use is anticipated.
* Assess for signs of anticholinergic adverse effects.
## Clinical Pearls
* Meftal spas should be taken with food or milk to minimize gastrointestinal upset.
* Due to the anticholinergic effects of hyoscine butylbromide, caution should be exercised in patients with conditions that can be exacerbated by these effects (e.g., prostatic hypertrophy, narrow-angle glaucoma, tachycardia).
* Avoid concurrent use with other NSAIDs.
* Short-term use is generally recommended to minimize risks.
This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local guidelines for complete details and to verify doses before prescribing.
